Latest Videos |view all videos
Patients who develop ovarian cancer appear to have better outcomes if they have a history of oral contraceptive use, according to a study by Mayo Clinic researchers published in the current issue of the journal BMC Cancer.
Preventive mastectomies that preserve the nipple and surrounding skin are as safe as more invasive surgeries for women who carry a genetic mutation called BCRA that raises their risk of developing breast cancer, a study led by Mayo Clinic has found.
Each year, about 200 to 400 Americans develop acinar cell carcinoma, a rare form of pancreatic cancer that has no effective standard of care.
Radiation therapy improves survival times in patients who are candidates for pancreatic cancer surgery.
Michael J. Levy, M.D., a consultant in Gastroenterology and Hepatology at Mayo Clinic’s campus in Rochester, Minnesota, discusses clinical utility, optimum specimen collection methods.
A new breast cancer risk prediction model combining histologic features of biopsied breast tissue from women with benign breast disease and individual patient demographic information more accurately classified breast cancer risk than the ...
Researchers at Mayo Clinic have shown that it is possible to detect endometrial cancer using tumor DNA picked up by ordinary tampons.
Mayo Clinic researcher Fergus Couch, Ph.D, discusses a study show that combined 77 common genetic variants into a single risk factor that can be used to improve the identification of women with an elevated risk of breast cancer.
John B. Kisiel, M.D., a gastroenterologist at Mayo Clinic's campus in Rochester, Minnesota, discusses a study that identified the source of cancer in patients’ gastrointestinal tracts by analyzing DNA markers from tumors.
Herceptin has been touted as a wonder drug for women with HER2-positive breast cancer, an aggressive form of the disease that is fueled by excess production of the HER2 protein.
Researchers found that a combination of ibrutinib and chemotherapy reduced the risk of death or cancer progression by 80 percent in patients with previously treated chronic lymphocytic leukemia.
Ruben A. Mesa, M.D., discusses of the targeted agent pacritinib significantly reduced the symptoms and burden of advanced myelofibrosis in patients